

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces Outcomes for EMBARK Study of Elevidys in Duchenne Muscular Dystrophy

TOKYO, October 31, 2023 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on October 30 (local time) regarding outcomes for EMBARK study in Duchenne muscular dystrophy (DMD) of microdystrophin gene therapy, Elevidys™ (Generic name: delandistrogene moxeparvovec, Development code: SRP-9001).

Please refer to the link below for details of the press release:

Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints

<https://www.roche.com/media/releases/med-cor-2023-10-30>

###